1. Executive Summary
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research Methods
1.4 Scope of this Report
1.4.1 Drug Types Excluded from this Report
1.5 Abbreviations Used in this Report
2. Introduction: Cancer, its Physiology, Burden and Treatment
2.1 The Physiology of Cancer
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival
2.2.3.1 The Developed World
2.2.3.2 The Developing World
2.3 Treating Tumours
2.3.1 Chemotherapy
2.3.2 Traditional Antineoplastics
2.3.3 Novel Antineoplastics
2.3.3.1 Kinase Receptor Antagonists
2.3.3.2 Other Novel Antineoplastics
2.3.4 Hormone Therapies
2.3.5 Active Immunotherapy
2.3.6 Passive Immunotherapy: Monoclonal Antibodies
3. The Global Cancer Drugs Market 2011-2021
3.1 Global Cancer Drugs Market 2009
3.2 Global Cancer Drugs Market Forecast 2011-2021
3.3 Traditional Antineoplastics Market Forecast 2011-2021
3.4 Novel Antineoplastics Market Forecast 2011-2021
3.5 Hormone Therapy Market Forecast 2011-2021
3.6 Immunotherapy Market Forecast 2011-2021
4. Cancer Drugs: Leading National Market Forecasts 2011-2021
4.1 National Cancer Drug Markets 2009
4.2 The US
4.3 Japan
4.4 The EU Top Five
4.5 BRIC Countries
4.5.1 Brazil
4.5.2 Russia
4.5.3 India
4.5.4 China
5. Top 10 Cancer Drugs: Sales Forecasts 2011-2021
5.1 Market Dominated by Monoclonal Antibodies
5.2 Avastin
5.2.1 Avastin Sales 2009
5.2.2 Recent Developments
5.2.3 Avastin Sales Forecast 2011-2021
5.3 MabThera
5.3.1 MabThera Sales 2009
5.3.2 Recent Developments
5.3.3 Sales Forecast 2011-2021
5.3.4 Increased Competition
5.3.5 Biosimilar MabThera
5.4 Herceptin
5.4.1 Herceptin Sales 2009
5.4.2 Recent Developments
5.4.3 Herceptin Sales Forecast 2011-2021
5.5 Glivec
5.5.1 Glivec Sales 2009
5.5.2 Glivec Sales Forecast 2011-2021
5.5.3 Tasigna Set to Replace Glivec
5.6 Taxotere
5.6.1 Taxotere Sales 2009
5.6.2 Patent Expiry
5.6.3 Taxotere Sales Forecast 2011-2021
5.7 Arimidex
5.7.1 Arimidex Sales 2009
5.7.2 Patent Expiry
5.8 Erbitux
5.8.1 Erbitux Sales 2009
5.8.2 Recent Developments
5.8.3 Erbitux Sales Forecast 2011-2021
5.9 Alimta
5.9.1 Alimta Sales 2009
5.9.2 Patent Disputes
5.9.3 Alimta Sales Forecast 2011-2021
5.10 Revlimid
5.10.1 Revlimid Sales 2009
5.10.2 Secondary Malignancies
5.10.3 Revlimid Sales Forecast 2011-2021
5.11 Velcade
5.11.1 Velcade Sales 2009
5.11.2 Recent Developments
5.11.3 Velcade Sales Forecast 2011-2021
6. Leading Companies in Cancer Drugs 2010
6.1 A Marketed Dominated by a Few Companies
6.2 Roche
6.2.1 Market Leader in 2009
6.2.2 Financial Performance 2010
6.2.3 Oncology Pipeline
6.2.4 Future Directions in Cancer
6.3 Novartis
6.3.1 Leading Cancer Drugs 2009
6.3.2 Financial Performance 2010
6.3.3 Oncology Pipeline
6.3.4 Future Directions in Cancer
6.4 AstraZeneca
6.4.1 Leading Cancer Drugs 2009
6.4.2 Financial Performance 2010
6.4.3 Oncology Pipeline
6.4.4 Future Directions in Cancer
6.5 Sanofi-Aventis
6.5.1 Leading Cancer Drugs 2009
6.5.2 Financial Performance 2010
6.5.3 Oncology Pipeline
6.5.4 Future Directions in Cancer
6.6 Eli Lilly
6.6.1 Leading Cancer Drugs 2009
6.6.2 Patent Issues 2010
6.6.3 Oncology Pipeline
6.6.4 Future Directions in Cancer
7. Pipeline Trends in Cancer 2011-2021
7.1 Immunotherapy: The Future of Cancer Treatment
7.1.1 Passive Immunotherapy
7.1.2 Active Immunotherapy
7.2 Lung Cancer Pipeline 2010
7.2.1 Line Extensions
7.2.2 BIBW 2992
7.2.3 MAGE-A3 ASCI
7.2.4 Talactoferrin
7.3 Breast Cancer Pipeline 2010
7.3.1 Line Extensions
7.3.2 Halaven
7.4 Colorectal Cancer Pipeline 2010
7.4.1 BAY 73-4506
7.4.2 KRX 0401
7.5 Stomach Cancer Pipeline 2010
7.5.1 Line Extensions
7.5.2 IMC1121B
7.6 Prostate Cancer Pipeline 2010
7.6.1 Provenge
7.6.2 MDV 3100
7.6.3 CB7630
7.6.4 Custirsen
8. SWOT Analysis for Cancer Drugs 2011-2021
8.1 SWOT Chart for the World Cancer Drugs Market 2011-2021
8.2 Strengths
8.2.1 High Profile Nature of Cancer
8.2.2 Off-Label Prescriptions are Common
8.2.3 Strong Drug Development Incentives
8.3 Weaknesses
8.3.1 Tumour Resistance
8.3.2 Pricing-Out the Developing World
8.4 Opportunities
8.4.1 Rising Incidence of Cancer
8.4.1.1 Aging Populations
8.4.1.2 Smoking
8.4.1.3 Obesity
8.4.1.4 The Developing World
8.4.2 Personalised Medicine
8.4.3 Live Licensing
8.4.4 Convenient Drugs
8.5 Threats
8.5.1 The Cost-Effectiveness Debate
8.5.2 Governments are a Leading Payer for Drugs
8.5.3 Efficacy, Toxicity and Alternative Treatments
8.6 Biosimilars and Generics: Opportunity or Threat?
8.7 Personalised Medicine
8.7.1 Cancer Heterogeneity
8.7.2 Pharmacogenomics
8.7.3 Genome Screening
8.7.4 Biomarkers and Diagnostics
8.7.5 Theranostics
9. Expert Opinion
9.1 Dr Janice M. Reichert
9.1.1 Main Challenges of Monoclonal Antibodies as Cancer Therapy
9.1.2 Main Opportunities
9.1.3 Side Effects of Monoclonal Antibodies
9.1.4 Future Developments and Pipelines
9.1.5 The Effect of Biosimilars
10. Conclusions
10.1 The US Will Continue to be the World's Largest Cancer Drug Market
10.2 India and China Will be the Fastest Growing National Markets
10.3 Monoclonal Antibodies Will Dominate the Market
10.3.1 Biosimilars Have Potential in Emerging Markets
10.4 Personalised Medicine Will Become More Commonplace
10.5 Pipelines for Many Cancer Types Are Strong
10.6 Concluding Remarks
List of Tables
Table 1.1 Abbreviations Used in the Report
Table 2.1 Leading Causes of Death Worldwide, 2008-2015
Table 2.2 Ten Most Common Cancers by Incidence, 2008
Table 2.3 Ten Most Common Cancers by Mortality, 2008 & 2015
Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK, 2009
Table 2.5 Categories of Oncology Drug, 2010
Table 2.6 Common Side-Effects of Traditional Antineoplastic Chemotherapy
Table 2.7 Subcategories of TANs
Table 3.1 Global Cancer Drugs Market by Category, 2009
Table 3.2 Cancer Immunotherapy Sales, 2009
Table 3.3 Traditional Antineoplastics Sales, 2009
Table 3.4 Global Cancer Drugs Market Forecast, 2009-2021
Table 3.5 Global Cancer Drugs Market Drivers and Restraints, 2011-2021
Table 3.6 Traditional Antineoplastics Market Forecast, 2009-2021
Table 3.7 Novel Antineoplastics Market Forecast, 2009-2021
Table 3.8 Novel Antineoplastics Drivers & Restraints, 2011-2021
Table 3.9 Hormone Therapy Market Forecast, 2009-2021
Table 3.10 Hormone Therapy Drivers & Restraints, 2011-2021
Table 3.11 Immunotherapy Drivers & Restraints, 2011-2021
Table 3.12 Immunotherapy Market Forecast, 2009-2021
Table 4.1 Global Cancer Drugs Market by Region, 2009
Table 4.2 Developed Markets Drivers and Restraints, 2011-2021
Table 4.3 Emerging Markets Drivers and Restraints, 2011-2021
Table 4.4 Global Cancer Drugs Market Forecast by Region, 2009-2021
Table 5.1 Top Ten Cancer Drugs Sales, 2009
Table 5.2 Top Ten Cancer Drugs: Key Facts, 2009
Table 5.3 Potential New Indications for Avastin, January 2010
Table 5.4 Avastin Sales Drivers and Restraints, 2011-2021
Table 5.5 Avastin Sales Forecast, 2009-2021
Table 5.6 MabThera Sales Forecast, 2009-2021
Table 5.7 MabThera Sales Drivers and Restraints, 2011-2021
Table 5.8 Herceptin Sales, 2007-2009
Table 5.9 Herceptin Sales Forecast, 2009-2021
Table 5.10 Herceptin Sales Drivers and Restraints, 2011-2021
Table 5.11 Glivec Sales by Region, 2009
Table 5.12 Glivec Sales Forecast, 2009-2021
Table 5.13 Glivec Sales Drivers and Restraints, 2011-2021
Table 5.14 Taxotere Approved Indications, 2010
Table 5.15 Taxotere Sales by Region, 2009
Table 5.16 Taxotere Sales Forecast, 2009-2021
Table 5.17 Taxotere Sales Drivers and Restraints, 2011-2021
Table 5.18 Arimidex Sales by Region, 2009
Table 5.19 Arimidex Sales by Region, Q1-Q3 2010
Table 5.20 Arimidex Sales Forecast, 2009-2021
Table 5.21 Arimidex Sales Drivers and Restraints, 2011-2021
Table 5.22 Erbitux Sales by Company, 2009
Table 5.23 Erbitux Sales Drivers and Restraints, 2011-2021
Table 5.24 Erbitux Sales Forecast, 2009-2021
Table 5.25 Alimta Sales by Region, 2009
Table 5.26 Alimta Sales Forecast, 2009-2021
Table 5.27 Alimta Sales Drivers and Restraints, 2011-2021
Table 5.28 Revlimid Sales Forecast, 2009-2021
Table 5.29 Revlimid Sales Drivers and Restraints, 2011-2021
Table 5.30 Velcade Sales by Company, 2009
Table 5.31 Velcade Sales Forecast, 2009-2021
Table 5.32 Velcade Sales Drivers and Restraints, 2011-2021
Table 6.1 Cancer Drugs Market by Company, 2009
Table 6.2 Roche Sales by Sector, 2009
Table 6.3 Roche Oncology Sales, 2009
Table 6.4 Roche Oncology Sales, H1 2010
Table 6.5 Roche Oncology Pipeline, November 2010
Table 6.6 Novartis Sales by Sector, 2009
Table 6.7 Novartis Oncology Sales, 2009
Table 6.8 Novartis Oncology Sales, Q1-Q3 2010
Table 6.9 Novartis Oncology Pipeline, 2010
Table 6.10 AstraZeneca Sales by Sector, 2009
Table 6.11 AstraZeneca Oncology Sales, 2009
Table 6.12 AstraZeneca Oncology Sales, Q1-Q3 2010
Table 6.13 AstraZeneca Oncology Pipeline, July 2010
Table 6.14 Sanofi-Aventis Sales by Sector, 2009
Table 6.15 Sanofi-Aventis Oncology Sales by Region, 2009
Table 6.16 Sanofi-Aventis Oncology Sales, H1 2010
Table 6.17 Sanofi-Aventis Oncology Pipeline, February 2010
Table 6.18 Eli Lilly Sales by Sector, 2009
Table 6.19 Eli Lilly Oncology Sales, 2009
Table 6.20 Eli Lilly Oncology Pipeline, 2010
Table 7.1 Number of Drug Candidates by Indication, 2009
Table 7.2 Abbreviations Used in Chapter 7
Table 7.3 Therapeutic Cancer Vaccines in Phase III, 2010
Table 7.4 Selected Lung Cancer Pipeline Candidates in Phase II & III, 2010
Table 7.5 Selected Breast Cancer Pipeline Candidates in Phase II & III, 2010
Table 7.6 Selected Colorectal Cancer Pipeline Candidates in Phase II & III, 2010
Table 7.7 Selected Stomach Cancer Pipeline Candidates in Phase II & III, 2010
Table 7.8 Selected Prostate Cancer Pipeline Candidates in Phase II & III, 2010
Table 8.1 SWOT Chart for the World Cancer Drugs Market, 2011-2021
Table 10.1 Global Cancer Drugs Market by Region, 2009-2021
Table 10.2 Global Cancer Drugs Market by Drug Type, 2009-2021
List of Figures
Figure 2.1 Leading Causes of Death Worldwide, 2008-2015
Figure 2.2 Ten Most Common Cancers by Incidence, 2008
Figure 2.3 Ten Most Common Cancers by Mortality, 2008
Figure 2.4 Ten Most Common Cancers by Mortality, 2015
Figure 2.5 Five-Year Survival Rates of Nine Cancers in the UK, 2009
Figure 3.1 Global Cancer Drugs Market by Category, 2009
Figure 3.2 Cancer Immunotherapy Sales, 2009
Figure 3.3 Traditional Antineoplastics Sales, 2009
Figure 3.4 Global Cancer Drugs Market Forecast, 2009-2021
Figure 3.5 Traditional Antineoplastics Market Forecast, 2009-2021
Figure 3.6 Novel Antineoplastics Market Forecast, 2009-2021
Figure 3.7 Hormone Therapy Market Forecast, 2009-2021
Figure 3.8 Immunotherapy Market Forecast, 2009-2021
Figure 4.1 Global Cancer Drugs Market by Region, 2009
Figure 4.2 Global Cancer Drugs Market by Region, 2015
Figure 4.3 Global Cancer Drugs Market by Region, 2021
Figure 4.4 US Cancer Drugs Market Forecast, 2009-2021
Figure 4.5 Japanese Cancer Drugs Market Forecast, 2009-2021
Figure 4.6 Top Five European Cancer Drugs Market Forecasts, 2009-2021
Figure 4.7 Brazilian Cancer Drugs Market Forecast, 2009-2021
Figure 4.8 Russian Cancer Drugs Market Forecast, 2009-2021
Figure 4.9 Indian Cancer Drugs Market Forecast, 2009-2021
Figure 4.10 BRIC National Cancer Drugs Markets, 2009
Figure 4.11 Chinese Cancer Drugs Market Forecast, 2009-2021
Figure 5.1 Top Ten Cancer Drugs Sales, 2009
Figure 5.2 Top Ten Cancer Drugs Sales by Drug Category, 2009
Figure 5.3 Avastin Sales Forecast, 2009-2021
Figure 5.4 MabThera Sales Forecast, 2009-2021
Figure 5.5 Herceptin Sales, 2007-2009
Figure 5.6 Herceptin Sales Forecast, 2009-2021
Figure 5.7 Glivec Sales by Region, 2009
Figure 5.8 Glivec Sales Forecast, 2009-2021
Figure 5.9 Taxotere Sales by Region, 2009
Figure 5.10 Taxotere Sales Forecast, 2009-2021
Figure 5.11 Arimidex Sales by Region, 2009
Figure 5.12 Arimidex Sales by Region, Q1-Q3 2010
Figure 5.13 Arimidex Sales Forecast, 2009-2021
Figure 5.14 Erbitux Sales by Company, 2009
Figure 5.15 Erbitux Sales Forecast, 2009-2021
Figure 5.16 Alimta Sales by Region, 2009
Figure 5.17 Alimta Sales Forecast, 2009-2021
Figure 5.18 Revlimid Sales Forecast, 2009-2021
Figure 5.19 Velcade Sales by Company, 2009
Figure 5.20 Velcade Sales Forecast, 2009-2021
Figure 6.1 Cancer Drugs Market by Company, 2009
Figure 6.2 Roche Sales by Sector, 2009
Figure 6.3 Roche Oncology Sales, 2009
Figure 6.4 Roche Oncology Sales, H1 2010
Figure 6.5 Novartis Sales by Sector, 2009
Figure 6.6 Novartis Oncology Sales, 2009
Figure 6.7 Novartis Oncology Sales, Q1-Q3 2010
Figure 6.8 AstraZeneca Sales by Sector, 2009
Figure 6.9 AstraZeneca Oncology Sales, 2009
Figure 6.10 AstraZeneca Oncology Sales, Q1-Q3 2010
Figure 6.11 Sanofi-Aventis Sales by Sector, 2009
Figure 6.12 Sanofi-Aventis Oncology Sales, 2009
Figure 6.13 Sanofi-Aventis Oncology Sales by Region, 2009
Figure 6.14 Sanofi-Aventis Oncology Sales, H1 2010
Figure 6.15 Eli Lilly Sales by Sector, 2009
Figure 6.16 Eli Lilly Oncology Sales, 2009
Figure 7.1 Number of Drug Candidates by Indication, 2009
Figure 7.2 Therapeutic Cancer Vaccines in Phase III, 2010